TY - JOUR
T1 - Multi-disciplinary Insights from the First European Forum on Visceral Myopathy 2022 Meeting
AU - Viti, Federica
AU - De Giorgio, Roberto
AU - Ceccherini, Isabella
AU - Ahluwalia, Arti
AU - Alves, Maria M.
AU - Baldo, Chiara
AU - Baldussi, Giannina
AU - Bonora, Elena
AU - Borrelli, Osvaldo
AU - Dall’Oglio, Luigi
AU - De Coppi, Paolo
AU - De Filippo, Carlotta
AU - de Santa Barbara, Pascal
AU - Diamanti, Antonella
AU - Di Lorenzo, Carlo
AU - Di Maulo, Ruggero
AU - Galeone, Antonio
AU - Gandullia, Paolo
AU - Hashmi, Sohaib K.
AU - Lacaille, Florence
AU - Lancon, Laurence
AU - Leone, Salvatore
AU - Mahé, Maxime M.
AU - Molnar, Maria Judit
AU - Palmitelli, Alessandro
AU - Perin, Silvia
AU - Prato, Alessio Pini
AU - Thapar, Nikhil
AU - Vassalli, Massimo
AU - Heuckeroth, Robert O.
N1 - Funding Information:
The European Forum on Visceral Myopathy (EFVM 2022) was funded by the European Joint Programme for Rare Diseases—Networking Support Scheme—Round 3, and by ‘POIC e dintorni’ patient advocacy organization ( https://poic-e-dintorni.org/ ). ROH is supported by the Irma and Norman Braman Endowment, the Suzi and Scott Lustgarten Center Endowment, NIH R01 DK128282, and The Children’s Hospital of Philadelphia Frontier Program Center for Precision Diagnosis and Therapy for Pediatric Motility Disorders.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/10
Y1 - 2023/10
N2 - Visceral myopathy is a rare, life-threatening disease linked to identified genetic mutations in 60% of cases. Mostly due to the dearth of knowledge regarding its pathogenesis, effective treatments are lacking. The disease is most commonly diagnosed in children with recurrent or persistent disabling episodes of functional intestinal obstruction, which can be life threatening, often requiring long-term parenteral or specialized enteral nutritional support. Although these interventions are undisputedly life-saving as they allow affected individuals to avoid malnutrition and related complications, they also seriously compromise their quality of life and can carry the risk of sepsis and thrombosis. Animal models for visceral myopathy, which could be crucial for advancing the scientific knowledge of this condition, are scarce. Clearly, a collaborative network is needed to develop research plans to clarify genotype–phenotype correlations and unravel molecular mechanisms to provide targeted therapeutic strategies. This paper represents a summary report of the first ‘European Forum on Visceral Myopathy’. This forum was attended by an international interdisciplinary working group that met to better understand visceral myopathy and foster interaction among scientists actively involved in the field and clinicians who specialize in care of people with visceral myopathy. Graphical Abstract: [Figure not available: see fulltext.]
AB - Visceral myopathy is a rare, life-threatening disease linked to identified genetic mutations in 60% of cases. Mostly due to the dearth of knowledge regarding its pathogenesis, effective treatments are lacking. The disease is most commonly diagnosed in children with recurrent or persistent disabling episodes of functional intestinal obstruction, which can be life threatening, often requiring long-term parenteral or specialized enteral nutritional support. Although these interventions are undisputedly life-saving as they allow affected individuals to avoid malnutrition and related complications, they also seriously compromise their quality of life and can carry the risk of sepsis and thrombosis. Animal models for visceral myopathy, which could be crucial for advancing the scientific knowledge of this condition, are scarce. Clearly, a collaborative network is needed to develop research plans to clarify genotype–phenotype correlations and unravel molecular mechanisms to provide targeted therapeutic strategies. This paper represents a summary report of the first ‘European Forum on Visceral Myopathy’. This forum was attended by an international interdisciplinary working group that met to better understand visceral myopathy and foster interaction among scientists actively involved in the field and clinicians who specialize in care of people with visceral myopathy. Graphical Abstract: [Figure not available: see fulltext.]
UR - http://www.scopus.com/inward/record.url?scp=85169164999&partnerID=8YFLogxK
U2 - 10.1007/s10620-023-08066-1
DO - 10.1007/s10620-023-08066-1
M3 - Review article
C2 - 37650948
AN - SCOPUS:85169164999
SN - 0163-2116
VL - 68
SP - 3857
EP - 3871
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 10
ER -